Argen-X lands AbbVie

April 25, 2016 News BioVox

Argen-X starts a collaboration with the global biopharmaceutical company AbbVie to develop and commercialize its novel immuno-oncology drug candidate, ARGX-115. ARGX-115 is  a preclinical-stage human antibody program targeting GARP, a protein believed to contribute to immunosuppressive effects of T-cells. 

Argen-X will receive an upfront payment of 35,3 million euros and subsequent preclinical milestone payments of 17,7 million dollar, for a total of 50 million euros. AbbVie may exercise an exclusive option to license the ARGX-115 program and assume responsibility for further clinical development and commercialization.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts